Melodiol Global Health Full Year 2023 Earnings: AU$0.019 Loss per Share (Vs AU$0.45 Loss in FY 2022)
MELODIOL GLOBAL HEALTH LIMITED To Carry Out 1-for-20 Reverse Stock Split On January 25th, 2024
Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
Phase 2 Psilocybin Therapy Trial For Patients With Treatment-Resistant PTSD: Latest Findings
Proactive News Headlines Including Antilles Gold, AuTECO Minerals, Latin Resources and HyTerra Ltd
Proactive News Headlines Including Piedmont Lithium, Tempus Resources, Creso Pharma Ltd and Southern Gold
Proactive news headlines including Silver Mines, Polymetals Resources, Creso Pharma and Core Lithium
Proactive news headlines including Magnis Energy Technologies, Pantoro Ltd, Creso Pharma and Krakatoa Resources
KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD
Proactive news headlines including American Rare Earths, Moho Resources, Golden Rim Resources and Duke Exploration
Proactive news headlines including Tempus Resources, Latrobe Magnesium, Kingston Resources and Caspin Resources
Proactive news headlines including Westar Resources, KGL Resources, Noxopharm and Eclipse Metals
BRIEF-Creso Pharma Ltd Provides Mernova Update
Creso Pharma Ltd (COPHF) Stock Declines -22.22% This Week; Should You Buy?
Creso Pharma buys Sierra Sage Herbs
Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs
Cannabis Movers & Shakers: Akerna, iAnthus, Cronos Group, WSU's Cannabis Research Center
Cronos Promotes John Griese, Former Exec At Nestlé, PepsiCo And Supreme Cannabis
Proactive news headlines including KGL Resources, Critical Resources, Blackstone Minerals and Suvo Strategic Minerals
No Data